Overview: Cyclin D1 Immunohistochemistry TestIntroduction: The Cyclin D1 Immunohistochemistry Test detects cyclin D1 protein to diagnose mantle cell lymphoma, causing lymph node swelling or fatigue. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected mantle cell lymphoma.
Other Names: Cyclin D1 IHC Assay, Mantle Cell Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Cyclin D1 testing began in the 1990s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects cyclin D1 to diagnose mantle cell lymphoma, guides treatment, and evaluates patients with lymph node swelling or fatigue.
Test Parameters: 1. Cyclin D1 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fatigue, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fatigue, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect cyclin D1 in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for mantle cell lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive cyclin D1 staining confirms mantle cell lymphoma, guiding chemotherapy or immunotherapy. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD5 IHC, FISH for t(11;14), or flow cytometry to confirm mantle cell lymphoma diagnosis.
Test Limitations: Not specific to mantle cell lymphoma; other conditions may express cyclin D1. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
